Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 8/20 | 1.00 |
| ▸ | MEN1 | O00255 | 7/20 | 1.00 |
| ▸ | MAPT | P10636 | 5/20 | 1.00 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 1.00 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 1.00 |
| ▸ | POLB | P06746 | 1/20 | 1.00 |
| ▸ | HTT | P42858 | 1/20 | 1.00 |
| ▸ | MAPK1 | P28482 | 6/20 | 0.81 |
| ▸ | TSHR | P16473 | 4/20 | 0.81 |
| ▸ | ALOX15 | P16050 | 3/20 | 0.81 |
| ▸ | TP53 | P04637 | 2/20 | 0.81 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.79 |
| ▸ | ACP1 | P24666 | 3/20 | 0.72 |
| ▸ | CYP1A2 | P05177 | 7/20 | 0.72 |
| ▸ | CYP3A4 | P08684 | 7/20 | 0.72 |
| ▸ | CYP2D6 | P10635 | 6/20 | 0.72 |
| ▸ | USP2 | O75604 | 5/20 | 0.72 |
| ▸ | HSD17B10 | Q99714 | 4/20 | 0.72 |
| ▸ | CYP2C19 | P33261 | 4/20 | 0.72 |
| ▸ | CLK4 | Q9HAZ1 | 4/20 | 0.72 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1085597 | 0.83 | ACP1 (0.87) | KMT2AMEN1MAPTALDH1A1KDM4E | |
| SCHEMBL3981553 | 0.81 | MAPK1 (0.81) | KMT2AMEN1MAPTALDH1A1KDM4E | |
| SCHEMBL3976459 | 0.80 | MAPT (0.67) | KMT2AMEN1MAPTALDH1A1KDM4E | |
| SCHEMBL1084021 | 0.80 | SMN1; SMN2 (0.79) | KMT2AMEN1MAPTALDH1A1KDM4E | |
| SCHEMBL3974887 | 0.80 | MAPK1 (0.82) | KMT2AMEN1MAPTALDH1A1KDM4E | |
| SCHEMBL4084663 | 0.79 | CYP1A2 (0.88) | KMT2AMEN1MAPTALDH1A1KDM4E | |
| SCHEMBL1289434 | 0.78 | MAPK1 (0.71) | KMT2AMEN1MAPTALDH1A1KDM4E | |
| SCHEMBL1289470 | 0.78 | MAPK1 (0.70) | KMT2AMEN1MAPTALDH1A1KDM4E | |
| Hydrochloric Acid SCHEMBL4511251 | 0.78 | MAPK1 (0.70) | KMT2AMEN1MAPTALDH1A1KDM4E | |
| SCHEMBL3460634 | 0.77 | CYP1A2 (0.79) | KMT2AMEN1MAPTALDH1A1POLB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11220486-B2 | Inhibitors of low molecular weight protein tyrosine phosphatase and uses thereof | LA JOLLA INSTITUTE OF ALLERGY & IMMUNOLOGY (US) | 2022-01-11 | — | — | US | disclosed |
| EP-3206689-B1 | INHIBITORS OF LOW MOLECULAR WEIGHT PROTEIN TYROSINE PHOSPHATASE AND USES THEREOF | LA JOLLA INST OF ALLERGY & IMMUNOLOGY (US) | 2021-12-08 | — | — | EP | disclosed |
| US-20200290977-A1 | Inhibitors of Low Molecular Weight Protein Tyrosine Phosphatase and Uses Thereof | LA JOLLA INSTITUTE OF ALLERGY & IMMUNOLOGY | 2020-09-17 | — | — | US | disclosed |
| US-10626094-B2 | Inhibitors of low molecular weight protein tyrosine phosphatase and uses thereof | Sanford Burnham Prebys Medical Discovery Institute (US) | 2020-04-21 | — | — | US | disclosed |
| US-20170247340-A1 | Inhibitors of Low Molecular Weight Protein Tyrosine Phosphatase and Uses Thereof | LA JOLLA INSTITUTE OF ALLERGY & IMMUNOLOGY | 2017-08-31 | — | — | US | disclosed |
| US-20170247340-A1 | Inhibitors of Low Molecular Weight Protein Tyrosine Phosphatase and Uses Thereof | LA JOLLA INSTITUTE OF ALLERGY & IMMUNOLOGY | 2017-08-31 | — | — | US | disclosed |
| WO-2016061280-A1 | INHIBITORS OF LOW MOLECULAR WEIGHT PROTEIN TYROSINE PHOSPHATASE AND USES THEREOF | LA JOLLA INSTITUTE OF ALLERGY & IMMUNOLOGY (US) | 2016-04-21 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11220486-B2 | Inhibitors of low molecular weight protein tyrosine phosphatase and uses thereof | ACP1, PTPRCAP, PTPA | KMT2A 567/4885MEN1 4778/4885MAPT 3143/4885 |
| US-10626094-B2 | Inhibitors of low molecular weight protein tyrosine phosphatase and uses thereof | ACP1, PTPRCAP, PTPA | KMT2A 567/4885MEN1 4778/4885MAPT 3143/4885 |
| US-20200290977-A1 | Inhibitors of Low Molecular Weight Protein Tyrosine Phosphatase and Uses Thereof | ACP1, PTPRCAP, PTPA | KMT2A 567/4885MEN1 4778/4885MAPT 3143/4885 |
| US-20170247340-A1 | Inhibitors of Low Molecular Weight Protein Tyrosine Phosphatase and Uses Thereof | ACP1, PTPRCAP, PTPA | KMT2A 567/4885MEN1 4778/4885MAPT 3143/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.